SCHEMBL6785704

SCHEMBL6785704

COC(=O)c1ccccc1NC(=O)/C=C(/C)c1ccc(F)c(F)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 3/20 0.56
TSHR P16473 2/20 0.53
CYP1A2 P05177 2/20 0.53
CYP2D6 P10635 1/20 0.53
CYP2C19 P33261 1/20 0.53
LMNA P02545 5/20 0.51
HPGD P15428 4/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
HTT P42858 1/20 0.51
KMT2A Q03164 3/20 0.47
KDM4E B2RXH2 6/20 0.46
MAPT P10636 3/20 0.46
HSD17B10 Q99714 2/20 0.46
APOBEC3A P31941 1/20 0.46
APOBEC3G Q9HC16 1/20 0.46
ALDH1A1 P00352 5/20 0.46
GAA P10253 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
LTB4R Q15722 1/20 0.45
MEN1 O00255 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6790601 0.88 TERT (0.72) TERTLMNASMN1; SMN2KMT2ALTB4R
SCHEMBL6784219 0.84 TERT (0.78) TERTTSHRCYP1A2CYP2D6CYP2C19
SCHEMBL6784249 0.83 TERT (0.56) TERTTSHRCYP1A2CYP2D6CYP2C19
SCHEMBL6783383 0.81 LTB4R (0.62) TERTTSHRCYP1A2CYP2D6CYP2C19
SCHEMBL6782877 0.81 HPGD (0.54) TERTTSHRCYP1A2CYP2D6CYP2C19
SCHEMBL6791993 0.81 CYP1A2 (0.53) TERTTSHRCYP1A2CYP2D6CYP2C19
SCHEMBL6785403 0.81 TERT (0.53) TERTTSHRCYP1A2CYP2D6CYP2C19
SCHEMBL6786460 0.81 TERT (0.53) TERTTSHRCYP1A2CYP2D6CYP2C19
SCHEMBL7241600 0.80 TERT (0.57) TERTTSHRCYP1A2CYP2D6CYP2C19
SCHEMBL7242175 0.79 TERT (0.56) TERTTSHRCYP1A2CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 TERT 1/4885TSHR 1693/4885CYP1A2 980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.